JP2024537910A - 安定した希釈準備済みカルフィルゾミブ組成物 - Google Patents

安定した希釈準備済みカルフィルゾミブ組成物 Download PDF

Info

Publication number
JP2024537910A
JP2024537910A JP2024523598A JP2024523598A JP2024537910A JP 2024537910 A JP2024537910 A JP 2024537910A JP 2024523598 A JP2024523598 A JP 2024523598A JP 2024523598 A JP2024523598 A JP 2024523598A JP 2024537910 A JP2024537910 A JP 2024537910A
Authority
JP
Japan
Prior art keywords
component
carfilzomib
pharma
acceptable salt
ready
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024523598A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024537910A5 (https=
Inventor
ラシクラル ヴァサナニ，パラス
パレーシュバーイー メータ，サンディップ
Original Assignee
カシーヴ バイオサイエンシズ，リミテッド・ライアビリティ・カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カシーヴ バイオサイエンシズ，リミテッド・ライアビリティ・カンパニー filed Critical カシーヴ バイオサイエンシズ，リミテッド・ライアビリティ・カンパニー
Publication of JP2024537910A publication Critical patent/JP2024537910A/ja
Publication of JP2024537910A5 publication Critical patent/JP2024537910A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024523598A 2021-10-21 2022-10-21 安定した希釈準備済みカルフィルゾミブ組成物 Pending JP2024537910A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202121047991 2021-10-21
IN202121047991 2021-10-21
PCT/IB2022/060145 WO2023067569A1 (en) 2021-10-21 2022-10-21 Stable ready to dilute composition of carfilzomib

Publications (2)

Publication Number Publication Date
JP2024537910A true JP2024537910A (ja) 2024-10-16
JP2024537910A5 JP2024537910A5 (https=) 2025-11-20

Family

ID=86058874

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024523598A Pending JP2024537910A (ja) 2021-10-21 2022-10-21 安定した希釈準備済みカルフィルゾミブ組成物

Country Status (7)

Country Link
US (2) US12440534B2 (https=)
EP (1) EP4419080A4 (https=)
JP (1) JP2024537910A (https=)
CN (1) CN118434408A (https=)
AU (1) AU2022369145A1 (https=)
CA (1) CA3235911A1 (https=)
WO (1) WO2023067569A1 (https=)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877205A (en) * 1996-06-28 1999-03-02 Board Of Regents, The University Of Texas System Parenteral paclitaxel in a stable non-toxic formulation
WO2015198257A1 (en) * 2014-06-26 2015-12-30 Intas Pharmaceuticals Ltd. Stable carfilzomib injection
WO2016116882A2 (en) * 2015-01-23 2016-07-28 Leiutis Pharmaceuticals Pvt Ltd Novel compositions of carfilzomib
WO2016185450A1 (en) * 2015-05-21 2016-11-24 Laurus Labs Private Limited An improved processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof
WO2018047074A1 (en) * 2016-09-07 2018-03-15 Cadila Healthcare Limited Sterile injectable compositions comprising drug micelles
US10098890B2 (en) * 2016-10-29 2018-10-16 Cipla Limited Stable carfilzomib formulations
WO2018138557A1 (en) * 2017-01-24 2018-08-02 Orbicular Pharmaceutical Technologies Pvt. Ltd. Ready-to-use carfilzomib compositions
US20260048003A1 (en) * 2020-01-10 2026-02-19 Amgen Inc. Stable cyclodextrin free carfilzomib formulation
CA3180338A1 (en) * 2020-04-15 2021-10-21 Kashiv Biosciences, Llc Stable ready to dilute formulations of carfilzomib

Also Published As

Publication number Publication date
US20240269224A1 (en) 2024-08-15
WO2023067569A1 (en) 2023-04-27
EP4419080A1 (en) 2024-08-28
CN118434408A (zh) 2024-08-02
AU2022369145A1 (en) 2024-05-23
US20260014226A1 (en) 2026-01-15
EP4419080A4 (en) 2025-12-24
CA3235911A1 (en) 2023-04-27
US12440534B2 (en) 2025-10-14

Similar Documents

Publication Publication Date Title
US10493079B2 (en) Stable carfilzomib formulations
US20110152360A1 (en) Liquid pharmaceutical formulations of docetaxel
US12083104B2 (en) Triple combination formulations for antiemetic therapy
EP3509569A1 (en) Sterile injectable compositions comprising drug micelles
US10512654B2 (en) Pharmaceutical composition including dutasteride and capsule formulation comprising the same
JP7837563B2 (ja) そのまま安定に希釈するためのカルフィルゾミブ製剤
JP2024537910A (ja) 安定した希釈準備済みカルフィルゾミブ組成物
WO2021033145A1 (en) Novel injectable formulations of artesunate
JP2020508332A (ja) 膀胱痛を治療するための膀胱内投与のための組成物
JP7606633B2 (ja) 医薬組成物及びアプレピタント注射液並びに凍結乾燥粉末注射剤
US20260097042A1 (en) Compound emulsion, preparation method therefor, and use thereof
AU2006257718A1 (en) Liquid pharmaceutical formulations of docetaxel

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251112